Document is current
Any future updates will be listed below
-
Authors
Halwe, Nico Joel https://orcid.org/0000-0002-7983-2808
Hamberger, Lea
Sehl-Ewert, Julia
Mache, Christin
Schön, Jacob https://orcid.org/0000-0002-9801-7972
Ulrich, Lorenz https://orcid.org/0000-0001-5004-806X
Calvelage, Sten
Tönnies, Mario
Fuchs, Jonas https://orcid.org/0000-0003-1974-212X
Bandawane, Pooja https://orcid.org/0000-0002-7729-5244
Loganathan, Madhumathi https://orcid.org/0000-0002-3751-8036
Abbad, Anass
Carreño, Juan Manuel
Bermúdez-González, Maria C.
Simon, Viviana https://orcid.org/0000-0002-6416-5096
Kandeil, Ahmed https://orcid.org/0000-0003-3253-6961
El-Shesheny, Rabeh https://orcid.org/0000-0002-8798-2240
Ali, Mohamed A. https://orcid.org/0000-0002-5615-3212
Kayali, Ghazi https://orcid.org/0000-0002-5387-1622
Budt, Matthias https://orcid.org/0000-0001-5960-515X
Hippenstiel, Stefan https://orcid.org/0000-0002-5146-1064
Hocke, Andreas C. https://orcid.org/0000-0002-6935-8612
Krammer, Florian https://orcid.org/0000-0003-4121-776X
Wolff, Thorsten https://orcid.org/0000-0001-7688-236X
Schwemmle, Martin https://orcid.org/0000-0002-2972-6855
Ciminski, Kevin https://orcid.org/0000-0001-5397-7497
Hoffmann, Donata https://orcid.org/0000-0003-4552-031X
Beer, Martin https://orcid.org/0000-0002-0598-5254
- License Information
-
More Information
Article History
Received: 20 December 2023
Accepted: 27 March 2024
First Online: 25 April 2024
Competing interests
: The Icahn School of Medicine at Mount Sinai has filed patent applications relating to influenza virus vaccines, SARS-CoV-2 serological assays and SARS-CoV-2 vaccines which list Florian Krammer as co‐inventor. Viviana Simon is also listed as co-inventor on patent applications for SARS-CoV-2 serological assays. Mount Sinai has spun out companies, Kantaro and Castlevax, to market the SARS-CoV-2 related technologies. Florian Krammer has consulted for Merck and Pfizer (before 2020), and is currently consulting for Pfizer, Seqirus, 3rd Rock Ventures, GSK and Avimex. The Krammer laboratory is also collaborating with Pfizer on animal models of SARS‐CoV‐2 and with Dynavax on universal influenza virus vaccines. All other authors declare no competing interests.
